SHILPAMEDNSEShilpa Medicare Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Fri, 12 Dec, 2025 · 11:48 IST

Shilpa Medicare gets EU initial approval for Rotigotine patch

Regulatory Product ApprovalBusiness Updates View source PDFExplain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.6%Reaction day
₹329.90
prior close
₹323.35
announcement price
In-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.3%-0.8% vs market
Pharmaceuticals peers, median of 155sector+0.2%-0.7% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+2.4
10m
+2.1
15m
+4.8
30m
+1.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.6+0.3-0.8+0.2-0.7
Next day
-2.1+0.8-2.8-0.1-2.0
2d
-1.0+0.1-1.2-0.5-0.6
3d
-1.7-0.8-0.9-1.2-0.5
4d
-3.3-1.1-2.2-1.4-1.9
5d
-1.5+0.2-1.7-0.5-1.0
1w
-1.6+1.6-3.2+0.5-2.1
15d
-4.2+2.5-6.7+0.5-4.7
1m
-10.5-2.7-7.8-2.7-7.7
2m
-2.1-0.3-1.8-3.3+1.2
3m
+2.2-8.9+11.2-8.6+10.8
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare received Initial Authorization from Europe for Rotigotine transdermal patch (1,2,3,4,6,8 mg/24h), a generic version of Neupro for Parkinson's disease and Restless Legs Syndrome. European market opportunity is about USD 222 million. Company has on-boarded a commercialization partner in Europe, with targeted launch in FY27. First transdermal patch approval in Europe, made at Unit VI, Bengaluru.

Likely market impact

Opens access to about USD 222 million European market, supports revenue growth from FY27.